Xcout Intel
Rallybio competitors & alternatives
The 12 closest competitors and alternatives to Rallybio among biotechnology companies — ranked by similarity to what Rallybio actually does, not by market-cap band.
Subscribe to see Rallybio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Rallybio
Rallybio is a clinical-stage biotechnology company that develops therapies for patients with severe and rare diseases, focusing on areas such as complement dysregulation and hematology. The company's pipeline includes therapeutic assets like C5 inhibitors designed to address significant unmet medical needs.
Rallybio at a glance
Rallybio is a biotechnology company headquartered in New Haven, United States. It is publicly listed (RLYB) with a market capitalisation of $95.2M. Xcout tracks 18 named people at Rallybio, including Jonathan I. Lieber (Chief Financial Officer & Treasurer).
Rallybio leadership
- Jonathan I. LieberChief Financial Officer & Treasurer
- Stephen UdenCo-Founder, President, Chief Executive Officer & Director
- Steve Uden, M.D.Co-Founder and Chief Executive Officer
- Martin W. MacKayCo-Founder & Chairman
- Martin Mackay, Ph.D.Co-Founder and Chairman
- Christine A NashDirector
12 more named people on record for Rallybio, with roles, board committees and tenure — see the full roster →
Rallybio funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $37M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Rallybio news
- AcquisitionM&A registration (S-4)
- AcquisitionM&A registration (S-4)
- AcquisitionM&A registration (S-4)
- AcquisitionM&A registration (S-4)
7 corporate events on record, with sources — see the full timeline →
Top 12 Rallybio competitors
Ranked by semantic similarity — how close each company is to Rallybio by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
SpliceBio is a clinical-stage genetic medicines company that develops gene therapies using a proprietary Protein Splicing platform. The company focuses on treating diseases caused by mutations in large genes, with a lead clinical program targeting Stargardt disease.
Similar biotechnology company
Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes. Nomacopan holds promise for a range of serious conditions, including paroxysmal nocturnal hemoglobinuria (PNH), Guillain-Barré syndrome (GBS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and bullous pemphigoid (BP). Akari's operations are headquartered in London, United Kingdom.
Biotech
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Similar biotechnology company
RAPT Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2015, the public company leverages its proprietary drug discovery platform to develop treatments for inflammatory and immunologic diseases.
Similar biotechnology company
Homology Medicines, Inc. is a clinical-stage genetic medicines company historically focused on transforming the lives of patients with rare diseases through genetic treatments.
Similar biotechnology company
AskBio is a clinical-stage gene therapy company that develops adeno-associated virus (AAV) gene therapies to treat genetic and complex disorders. The company focuses on advancing genetic medicine through its proprietary technology platforms, manufacturing processes, and clinical trials.
Biotech
ABIONYX Pharma is a biotech company that develops innovative therapies for severe diseases and rare conditions with no effective existing treatments. The company focuses on creating drugs for renal and ophthalmological diseases, as well as new HDL vectors for targeted drug delivery and treatments for severe inflammation and sepsis.
Biotech
Healx is an AI-native pharmaceutical company that uses artificial intelligence and technology to discover and develop new treatments for rare diseases. The company redevelops, combines, and enhances known compounds to build a drug pipeline aimed at delivering effective therapies to patients.
Similar biotechnology company
Travere Therapeutics is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing, and delivering life-changing therapies for people living with rare diseases.
Biotech
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Similar biotechnology company
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, with additional operations in San Diego, California. The company focuses on the discovery and development of novel biopharmaceuticals for cardiovascular and other severe diseases.
Similar biotechnology company
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Rallybio and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Rallybioand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →